 |
|
|
 |
|
Obese Men Face Twin Threat From Prostate Cancer
Delayed diagnosis, less successful surgery, pair of studies finds
By Ed Edelson HealthDay Reporter
|
 |  |  |  | Related Healthscout Videos |  |
|
FRIDAY, Aug. 8 (HealthDay News) -- The standard screening test for prostate cancer may not be accurate for obese men, leaving them more vulnerable to the disease, and surgery is less likely to be effective for them, a new pair of studies found.
"Obese men are more likely to be diagnosed with an aggressive form of the disease," said Dr. Stephen Freedland, an associate professor of urology and pathology at the Duke University Prostate Center, and an author of one of the studies.
Text Continues Below

The reason: The blood test that looks for elevated levels of the protein prostate-specific antigen (PSA), indicating a heightened cancer risk, doesn't seem as reliable for obese men, Freedland said.
"Our assumption is that these men have more blood volume, so PSA gets diluted, he said. "By the time obese men get to elevated levels, the cancer is more advanced."
The study, published online Friday in the journal BJU International included nearly 3,400 men who had PSA tests. The researchers found that the risk of an aggressive cancer was doubled in obese men diagnosed because of high PSA levels. No such association was found for obese men diagnosed by a digital rectal examination, in which the physician feels for an abnormally large prostate gland.
Prostate cancer is suspected when the PSA reading is 4 or higher. The current recommendation is for men aged 50 and older to be offered an annual PSA test, with explanations of its possible risks and benefits. A federal preventive medicine committee this week said that PSA screening should not be done for men aged 75 and older because the risks outweigh the benefits.
"I'm not sure that we should check obese men more often," Freedland said. "But we should have a higher [PSA] index of suspicion of what is not normal -- 3.4 rather than 4; for really obese men, 3.2."
Page: 1 | 2 | Next >>
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 8/8/2008
|
 |

SOURCES: Stephen Freedland, M.D., associate professor, urology and pathology, Jayakrishnan Jayachandran, M.D., urology oncolgy fellow, Duke University Prostate Cancer Center, Durham, N.C.; Aug. 8, 2008, BJU International, online
|